P-323 RAS mutations in metastatic colorectal cancer in central Tunisia

Abstract

Colorectal cancer (CRC) is the most common cancer worldwide. RAS oncogene is one of the most important targets for drug development in metastatic colorectal cancers. Its mutation predicts cetuximab resistance and a worse prognosis. To our knowledge, the prevalence of RAS mutations in central Tunisia has not been previously reported.